Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Thomas G. Wells"'
Publikováno v:
European Journal of Clinical Pharmacology
Purpose This open-label, multicenter, single-dose study characterized the pharmacokinetics and short-term safety of azilsartan medoxomil (AZL-M) in hypertensive pediatric subjects (12–16 years [cohort 1a; n = 9]; 6–11 years [cohort 2; n = 8]; 4
The National Institutes of Health (NIH) defines a clinical trial as “a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1a350007cd3c88741b9ed0a66ed44e
https://doi.org/10.1016/b978-0-323-35955-9.00027-1
https://doi.org/10.1016/b978-0-323-35955-9.00027-1
Autor:
Thomas G. Wells, Douglas L. Blowey, Reinilde Heyrman, Daniel E. Salazar, Janice E. Sullivan, Joseph R. Sherbotie, SaeHeum Song, Shashank Rohatagi, Jeffrey L. Blumer
Publikováno v:
Pediatric Drugs. 14:401-409
Background: The prevalence and importance of hypertension in younger patients is becoming increasingly recognized; however, only a limited number of clinical trials have been conducted in the pediatric population. Objective: The aim of this study was
Autor:
R. Massaad, Shahnaz Shahinfar, Nicholas J. A. Webb, Chun Lam, Christine McCrary Sisk, Gilbert W. Gleim, Emanuela P. Santoro, Thomas G. Wells
Publikováno v:
Kidney International. 82:819-826
Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely used in adults; however, thei
Autor:
Laura P. James, Pippa Simpson, Jeffrey L. Blumer, Robert M. Ward, Janice E. Sullivan, Shun-Hwa Li, Karen M. Redwine, Lee Howard, Thomas G. Wells, Ke Yan
Publikováno v:
Pediatric Nephrology. 27:1937-1942
Ambulatory blood pressure monitoring (ABPM) has been proposed as a useful tool for more accurately diagnosing hypertension (HTN) and evaluating blood pressure (BP) response in pediatric anti-hypertensive trials. ABPM captures multiple BP measurements
Autor:
Victor Shi, Susan Solar-Yohay, Guangyang Han, Jeffrey L. Blumer, Thomas G. Wells, Johan Vande Walle, Rejane de Paula Meneses, Mieczysław Litwin, Jose Pacheco Neto, Kevin E.C. Meyers
Publikováno v:
The Journal of Clinical Hypertension. 13:357-365
The effectiveness and safety of valsartan have not been assessed in hypertensive children. Therefore, hypertensive patients aged 6 to 16 years (n=261) were randomized to receive weight-stratified low- (10/20 mg), medium- (40/80 mg), or high-dose (80/
Autor:
Emanuela P. Santoro, Thomas G. Wells, Shahnaz Shahinfar, Gilbert W. Gleim, Chun Lam, Tom Loeys, Juergen Strehlau, Nicholas J. A. Webb, Denise Manas
Publikováno v:
Clinical Journal of the American Society of Nephrology. 5:417-424
Background and objectives: No large, randomized, double-blind trials in children with proteinuria treated with angiotensinconverting enzyme inhibitors or angiotensin receptor blockers have previously been reported. Design, setting, participants, & me
Autor:
Victor Shi, Susan Solar-Yohay, Gangadhar Sunkara, Jeffrey L. Blumer, Thomas G. Wells, Donald L. Batisky
Publikováno v:
The Journal of Clinical Pharmacology. 49:235-241
An open-label, single-dose study is conducted in 26 children with hypertension to characterize the pharmacokinetics of valsartan. Valsartan is administered as an oral suspension (dose of 2 mg/kg), with the maximum single dose being 80 mg. Subjects ar
Publikováno v:
Annals of Pharmacotherapy. 42:1388-1395
Background:The angiotensin-receptor blocker candesartan cilexetil is a well-toleraled antihypertensive agent with demonstrated benefits in adults with hypertension. However, there are few data supporting its use in children with hypertension.Objectiv
Autor:
Frank Tenney, Ronald J. Hogg, Wayne Shaw, Shahnaz Shahinfar, Jeffrey L. Blumer, M.-W. Lo, Ronda K. Rippley, Angela Delucchi, E. L. Hand, Beth A. Vogt, Donald L. Batisky, Deborah Panebianco, Graciela Sakihara, Thomas G. Wells
Publikováno v:
Pediatric Nephrology. 22:695-701
The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients6 years of age; the remaining children received lisinopril tablets, the